Top 11 Hepatitis treatment startups in USA
Apr 10, 2026
|
Like
18
1
Funding: $1.2B
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
2
Funding: $2.4B
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
3
Funding: $765M
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
4
Funding: $505.6M
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of their cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of their cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.
5
Funding: $498.5M
Terns Pharmaceuticals is a biopharmaceutical company that focuses on discovering therapies that will improve the global nonalcoholic steatohepatitis (NASH) burden.
Terns Pharmaceuticals is a biopharmaceutical company that focuses on discovering therapies that will improve the global nonalcoholic steatohepatitis (NASH) burden.
6
Funding: $290M
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
7
Funding: $265.2M
Precision BioSciences is a genome editing company dedicated to improving life. Our team seeks to solve – not just treat, but solve – significant problems in oncology, genetic disease, agriculture, and beyond via its proprietary ARCUS genome editing platform.
Precision BioSciences is a genome editing company dedicated to improving life. Our team seeks to solve – not just treat, but solve – significant problems in oncology, genetic disease, agriculture, and beyond via its proprietary ARCUS genome editing platform.
8
Funding: $200.4M
Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.
Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.
9
Funding: $34.8M
Aethlon Medical creates immunotherapeutic devices to combat infectious disease and cancer.
Aethlon Medical creates immunotherapeutic devices to combat infectious disease and cancer.
10
Funding: $11.4M
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
11
Funding: $3M
Chromis Therapeutics develops curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform.
Chromis Therapeutics develops curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform.
★
See also:
